Total Neoadjuvant Therapy in Rectal Cancer Treatment

Total Neoadjuvant Therapy in Rectal Cancer Treatment

This is a randomized, controlled, parallel study to determine the efficiency and safety of total neoadjuvant therapy in rectal cancer treatment.

In this randomized, controlled, parallel study we will comparison total neoadjuvant therapy with standard neoadjuvant therapy in rectal cancer treatment. Complete pathological response rate will be the primary endpoint in patients, who will undergoing surgery. In cases of complete clinical response we will provide "watch and wait" approach. Compliance of treatment and oncologic results will be the second endpoint.

Inclusion Criteria:

• Have signed an approved informed consent form for the stud;
• Histologically confirmed rectal adenocarcinoma low (cT2-4N0-2M0) or mid rectum (сТ2-T4N1-2M0);

Exclusion Criteria:

• rectal cancer recurrence;
• Primary-multiple tumours of other localizations;
• pelvis radiotherapy in anamnesis;
• pregnancy, breastfeeding;
• distant metastasis;
• ECOG score 3-4